Sawyer & Company’s GSK GSK Stock Holding History

Sawyer & Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$5K	–	182
2021 Q3	$5K	Hold	100	–	–	﹤0.01%	175
2021 Q2	$5K	Hold	100	–	–	﹤0.01%	164
2021 Q1	$4K	Sell	100 -280	-74%	-$12.7K	﹤0.01%	159
2020 Q4	$17K	Sell	380 -280	-42%	-$12.9K	0.01%	137
2020 Q3	$31K	Sell	660 -460	-41%	-$23K	0.02%	127
2020 Q2	$57K	Hold	1,120	–	–	0.04%	124
2020 Q1	$53K	Hold	1,120	–	–	0.04%	116
2019 Q4	$66K	Hold	1,120	–	–	0.04%	119
2019 Q3	$60K	Hold	1,120	–	–	0.04%	116
2019 Q2	$56K	Hold	1,120	–	–	0.04%	123
2019 Q1	$59K	Hold	1,120	–	–	0.04%	120
2018 Q4	$53K	Sell	1,120 -700	-38%	-$34.5K	0.04%	120
2018 Q3	$91K	Hold	1,820	–	–	0.06%	118
2018 Q2	$92K	Hold	1,820	–	–	0.06%	119
2018 Q1	$89K	Hold	1,820	–	–	0.06%	119
2017 Q4	$81K	Buy	+1,820	New	+$84.1K	0.05%	116

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Sawyer & Company's GSK Position: Q4 2021 in Review

Sawyer & Company sold out of GSK (GSK) in Q4 2021, closing a stake of 100 shares — an estimated $5K sold.

Sawyer & Company first reported a position in GSK in Q4 2017 and held it in 16 quarters. The position peaked at $92K in Q2 2018. 919 funds tracked by Wall St. Rank hold GSK as of Q4 2021.

Sawyer & Company reported no remaining GSK position as of Q4 2021 after selling out during the quarter.
Sawyer & Company sold 100 GSK shares in Q4 2021, an estimated $5K.
Sawyer & Company first reported a position in GSK in Q4 2017 and held it in 16 quarters.
Sawyer & Company's GSK position peaked at $92K in Q2 2018.
919 funds tracked by Wall St. Rank held GSK as of Q4 2021.

Based on Sawyer & Company's 13F filing for Q4 2021, filed 14 Jan 2022.